Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans

Kozi Hosoya, Hitoshi Minakuchi, Shu Wakino, Keiko Fujimura, Kazuhiro Hasegawa, Motoaki Komatsu, Ayumi Yoshifuji, Koji Futatsugi, Keisuke Shinozuka, Naoki Washida, Takeshi Kanda, Hirobumi Tokuyama, Koichi Hayashi, Hiroshi Itoh

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

In this study, we examined the association between chronic kidney disease (CKD) and insulin resistance. In a patient cohort with nondiabetic stages 2-5 CKD, estimated glomerular filtration rate (eGFR) was negatively correlated and the plasma aldosterone concentration was independently associated with the homeostasis model assessment of insulin resistance. Treatment with the mineralocorticoid receptor blocker spironolactone ameliorated insulin resistance in patients, and impaired glucose tolerance was partially reversed in fifth/sixth nephrectomized rats. In these rats, insulin-induced signal transduction was attenuated, especially in the adipose tissue. In the adipose tissue of nephrectomized rats, nuclear mineralocorticoid receptor expression, expression of the mineralocorticoid receptor target molecule SGK-1, tissue aldosterone content, and expression of the aldosterone-producing enzyme CYP11B2 increased. Mineralocorticoid receptor activation in the adipose tissue was reversed by spironolactone. In the adipose tissue of nephrectomized rats, asymmetric dimethylarginine (ADMA; an uremic substance linking uremia and insulin resistance) increased, the expression of the ADMA-degrading enzymes DDAH1 and DDAH2 decreased, and the oxidative stress increased. All of these changes were reversed by spironolactone. In mature adipocytes, aldosterone downregulated both DDAH1 and DDAH2 expression, and ADMA inhibited the insulin-induced cellular signaling. Thus, activation of mineralocorticoid receptor and resultant ADMA accumulation in adipose tissue has, in part, a relevant role in the development of insulin resistance in CKD.

Original languageEnglish
Pages (from-to)749-760
Number of pages12
JournalKidney International
Volume87
Issue number4
DOIs
Publication statusPublished - 2015 Apr 8

Fingerprint

Mineralocorticoid Receptors
Spironolactone
Chronic Renal Insufficiency
Insulin Resistance
Adipose Tissue
Aldosterone
Cytochrome P-450 CYP11B2
Insulin
Disease Resistance
Glucose Intolerance
Uremia
Enzymes
Cytoplasmic and Nuclear Receptors
Glomerular Filtration Rate
Adipocytes
Signal Transduction
Oxidative Stress
Homeostasis
Down-Regulation

Keywords

  • ADMA
  • Aldosterone
  • CKD
  • Insulin resistance
  • Mineralocorticoid receptor

ASJC Scopus subject areas

  • Nephrology

Cite this

Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans. / Hosoya, Kozi; Minakuchi, Hitoshi; Wakino, Shu; Fujimura, Keiko; Hasegawa, Kazuhiro; Komatsu, Motoaki; Yoshifuji, Ayumi; Futatsugi, Koji; Shinozuka, Keisuke; Washida, Naoki; Kanda, Takeshi; Tokuyama, Hirobumi; Hayashi, Koichi; Itoh, Hiroshi.

In: Kidney International, Vol. 87, No. 4, 08.04.2015, p. 749-760.

Research output: Contribution to journalArticle

Hosoya, Kozi ; Minakuchi, Hitoshi ; Wakino, Shu ; Fujimura, Keiko ; Hasegawa, Kazuhiro ; Komatsu, Motoaki ; Yoshifuji, Ayumi ; Futatsugi, Koji ; Shinozuka, Keisuke ; Washida, Naoki ; Kanda, Takeshi ; Tokuyama, Hirobumi ; Hayashi, Koichi ; Itoh, Hiroshi. / Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans. In: Kidney International. 2015 ; Vol. 87, No. 4. pp. 749-760.
@article{2baef5ed6a3941aab6af8b502716bf32,
title = "Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans",
abstract = "In this study, we examined the association between chronic kidney disease (CKD) and insulin resistance. In a patient cohort with nondiabetic stages 2-5 CKD, estimated glomerular filtration rate (eGFR) was negatively correlated and the plasma aldosterone concentration was independently associated with the homeostasis model assessment of insulin resistance. Treatment with the mineralocorticoid receptor blocker spironolactone ameliorated insulin resistance in patients, and impaired glucose tolerance was partially reversed in fifth/sixth nephrectomized rats. In these rats, insulin-induced signal transduction was attenuated, especially in the adipose tissue. In the adipose tissue of nephrectomized rats, nuclear mineralocorticoid receptor expression, expression of the mineralocorticoid receptor target molecule SGK-1, tissue aldosterone content, and expression of the aldosterone-producing enzyme CYP11B2 increased. Mineralocorticoid receptor activation in the adipose tissue was reversed by spironolactone. In the adipose tissue of nephrectomized rats, asymmetric dimethylarginine (ADMA; an uremic substance linking uremia and insulin resistance) increased, the expression of the ADMA-degrading enzymes DDAH1 and DDAH2 decreased, and the oxidative stress increased. All of these changes were reversed by spironolactone. In mature adipocytes, aldosterone downregulated both DDAH1 and DDAH2 expression, and ADMA inhibited the insulin-induced cellular signaling. Thus, activation of mineralocorticoid receptor and resultant ADMA accumulation in adipose tissue has, in part, a relevant role in the development of insulin resistance in CKD.",
keywords = "ADMA, Aldosterone, CKD, Insulin resistance, Mineralocorticoid receptor",
author = "Kozi Hosoya and Hitoshi Minakuchi and Shu Wakino and Keiko Fujimura and Kazuhiro Hasegawa and Motoaki Komatsu and Ayumi Yoshifuji and Koji Futatsugi and Keisuke Shinozuka and Naoki Washida and Takeshi Kanda and Hirobumi Tokuyama and Koichi Hayashi and Hiroshi Itoh",
year = "2015",
month = "4",
day = "8",
doi = "10.1038/ki.2014.348",
language = "English",
volume = "87",
pages = "749--760",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans

AU - Hosoya, Kozi

AU - Minakuchi, Hitoshi

AU - Wakino, Shu

AU - Fujimura, Keiko

AU - Hasegawa, Kazuhiro

AU - Komatsu, Motoaki

AU - Yoshifuji, Ayumi

AU - Futatsugi, Koji

AU - Shinozuka, Keisuke

AU - Washida, Naoki

AU - Kanda, Takeshi

AU - Tokuyama, Hirobumi

AU - Hayashi, Koichi

AU - Itoh, Hiroshi

PY - 2015/4/8

Y1 - 2015/4/8

N2 - In this study, we examined the association between chronic kidney disease (CKD) and insulin resistance. In a patient cohort with nondiabetic stages 2-5 CKD, estimated glomerular filtration rate (eGFR) was negatively correlated and the plasma aldosterone concentration was independently associated with the homeostasis model assessment of insulin resistance. Treatment with the mineralocorticoid receptor blocker spironolactone ameliorated insulin resistance in patients, and impaired glucose tolerance was partially reversed in fifth/sixth nephrectomized rats. In these rats, insulin-induced signal transduction was attenuated, especially in the adipose tissue. In the adipose tissue of nephrectomized rats, nuclear mineralocorticoid receptor expression, expression of the mineralocorticoid receptor target molecule SGK-1, tissue aldosterone content, and expression of the aldosterone-producing enzyme CYP11B2 increased. Mineralocorticoid receptor activation in the adipose tissue was reversed by spironolactone. In the adipose tissue of nephrectomized rats, asymmetric dimethylarginine (ADMA; an uremic substance linking uremia and insulin resistance) increased, the expression of the ADMA-degrading enzymes DDAH1 and DDAH2 decreased, and the oxidative stress increased. All of these changes were reversed by spironolactone. In mature adipocytes, aldosterone downregulated both DDAH1 and DDAH2 expression, and ADMA inhibited the insulin-induced cellular signaling. Thus, activation of mineralocorticoid receptor and resultant ADMA accumulation in adipose tissue has, in part, a relevant role in the development of insulin resistance in CKD.

AB - In this study, we examined the association between chronic kidney disease (CKD) and insulin resistance. In a patient cohort with nondiabetic stages 2-5 CKD, estimated glomerular filtration rate (eGFR) was negatively correlated and the plasma aldosterone concentration was independently associated with the homeostasis model assessment of insulin resistance. Treatment with the mineralocorticoid receptor blocker spironolactone ameliorated insulin resistance in patients, and impaired glucose tolerance was partially reversed in fifth/sixth nephrectomized rats. In these rats, insulin-induced signal transduction was attenuated, especially in the adipose tissue. In the adipose tissue of nephrectomized rats, nuclear mineralocorticoid receptor expression, expression of the mineralocorticoid receptor target molecule SGK-1, tissue aldosterone content, and expression of the aldosterone-producing enzyme CYP11B2 increased. Mineralocorticoid receptor activation in the adipose tissue was reversed by spironolactone. In the adipose tissue of nephrectomized rats, asymmetric dimethylarginine (ADMA; an uremic substance linking uremia and insulin resistance) increased, the expression of the ADMA-degrading enzymes DDAH1 and DDAH2 decreased, and the oxidative stress increased. All of these changes were reversed by spironolactone. In mature adipocytes, aldosterone downregulated both DDAH1 and DDAH2 expression, and ADMA inhibited the insulin-induced cellular signaling. Thus, activation of mineralocorticoid receptor and resultant ADMA accumulation in adipose tissue has, in part, a relevant role in the development of insulin resistance in CKD.

KW - ADMA

KW - Aldosterone

KW - CKD

KW - Insulin resistance

KW - Mineralocorticoid receptor

UR - http://www.scopus.com/inward/record.url?scp=84926527017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926527017&partnerID=8YFLogxK

U2 - 10.1038/ki.2014.348

DO - 10.1038/ki.2014.348

M3 - Article

C2 - 25337775

AN - SCOPUS:84926527017

VL - 87

SP - 749

EP - 760

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 4

ER -